Our study demonstrates for the first time that copeptin levels predict the presence of biopsy-proven NAFLD in obese individuals, regardless of body adiposity and the coexistence of other metabolic disorders. Here, AVP is linked to metabolic dysfunction-associated steatotic liver disease.